NASDAQ: BIAFBioaffinity Technologies Inc Stock
$0.51+0.01 (+2%)
Updated Apr 22, 2025
BIAF Price
$0.51
Fair Value Price
N/A
Market Cap
$9.31M
52 Week Low
$0.24
52 Week High
$2.99
P/E
-0.68x
P/B
3.58x
P/S
1.18x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.36M
Earnings
-$9.04M
Gross Margin
36.1%
Operating Margin
-95.45%
Profit Margin
-96.6%
Debt to Equity
1.5
Operating Cash Flow
-$7M
Beta
1.28
Next Earnings
May 20, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BIAF Overview
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BIAF's potential to beat the market
- BIAF doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
BIAF
RankedUnranked of 43
RankedUnranked of 43
Be the first to know about important BIAF news, forecast changes, insider trades & much more!
BIAF News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BIAF scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BIAF is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BIAF is poor value based on its book value relative to its share price (3.58x), compared to the US Diagnostics & Research industry average (3.3x)
P/B vs Industry Valuation
BIAF is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BIAF due diligence checks available for Premium users.
Valuation
BIAF fair value
Fair Value of BIAF stock based on Discounted Cash Flow (DCF)
Price
$0.51
Fair Value
$0.13
Overvalued by
292.41%
BIAF is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BIAF price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.68x
Industry
36.47x
Market
28.14x
BIAF price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.58x
Industry
3.3x
BIAF is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BIAF's financial health
Profit margin
Revenue
$2.2M
Net Income
-$3.0M
Profit Margin
-134.4%
BIAF's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BIAF's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.5M
Liabilities
$3.9M
Debt to equity
1.5
BIAF's short-term liabilities ($3.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIAF's short-term assets ($2.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIAF's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.7M
Investing
-$1.0
Financing
$2.0M
BIAF's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BIAF vs Diagnostic & Research Stocks
Bioaffinity Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.